针对选择性葡萄糖结合物疫苗的多重体,多价值的融合载体蛋白质,同时向金黄色葡萄球菌和原菌
Charlotte Sorieul1,2, Bartal Mikladal2, Dung-Yeh Wu1,2
1Leiden Institute of Chemistry, Leiden University Einsteinweg 55 2333 CC Leiden Netherlands.
Chemical science
|March 5, 2025
概括
一种结合黄金葡萄球菌 (Staphylococcus aureus) 和空气菌 (Pseudomonas aeruginosa) 成分的新型多种皮托普疫苗显示出对抗抗菌素耐药性的承诺. 这种创新方法针对的是多微生物感染,并加强了疫苗开发战略.
科学领域:
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
- 疫苗开发 疫苗开发
背景情况:
- * *金黄色葡萄球菌*和空气真菌假菌*是主要的抗微生物耐药性病原体,经常在慢性伤口等多微生物感染中发现.
- *这些细菌显著降低了抗生素的疗效,尽管进行了广泛的研究,但这给临床带来了巨大的负担.
- * 目前,没有疫苗可用于*S. aureus*或*P. aeruginosa*.
研究的目的:
- * 开发一种新型的多皮托普疫苗,针对金黄色葡萄球菌和空气真菌.
- * 创建一个疫苗构造,利用局部选择性结合来保护抗原和有效性.
- * 证明对这些具有挑战性的病原体进行功能性保护.
主要方法:
- *通过将*S. aureus*囊型多糖类血清型8与一种嵌合蛋白 (Hla-PcrV) 相结合,制造了一种多皮托普疫苗.
- *采用选择性结合策略,使用胺标签来维持表位结构和抗原性.
- *评估了多价值体,多重体和多病原体结构的疗效.
主要成果:
- *开发的疫苗成功地产生了针对所有三个向抗原的抗体 (*S. aureus*多糖,Hla和PcrV).
- * 功能性保护被证明是有效的,这表明疫苗对抗病原体的有效性.
- * 该研究证实了在疫苗制造中选择性结合的潜力.
结论:
- * 这一概念验证突出了针对多微生物感染的先进多价值疫苗的潜力.
- * 开发的疫苗策略显示出对抗由*S. aureus*和*P. aeruginosa*引起的抗菌素耐药性的承诺.
- *选择性结合是创建复杂疫苗配方的强大工具.
更多相关视频
相关概念视频
Cross-reactivity
30.9K
Overview
30.9K
Antigens Involved in Adaptive Immunity
435
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
435
Tagging and Fusion Proteins
6.6K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.6K
Hybridoma Technology
14.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.0K


